From PCOS to PMOS and Beyond: Low-Carbohydrate and Orthomolecular Medicine as Foundations for Systems-Based Longevity Medicine

Abstract

Background: In 2026, an international consensus renamed polycystic ovary syndrome (PCOS) polyendocrine metabolic ovarian syndrome (PMOS), acknowledging its broader endocrine–metabolic phenotype without changing treatment guidance. Objective: To evaluate carbohydrate restriction as a phenotype-sensitive research and care option; identify unresolved nutritional–redox questions, with vitamin C as an index molecule; and set out a falsifiable disease-specific application of the insulin–cortisol–vitamin C (ICV) heuristic.Approach: A selective, non-systematic narrative synthesis of international guidance, dietary meta-analyses, oxidative-stress research, and ascorbate physiology; no original patient data or pooled analyses. Findings: Recent short-term ketogenic-diet meta-analyses report improvements in weight and selected metabolic indicators, including some advantages against comparison diets. Considerable heterogeneity, overlapping studies, limited reproductive endpoints, and uncertainty about weight-independent and long-term effects prevent blanket treatment claims. Stress-system findings are variable; generalized cortisol dysregulation cannot be assumed. Ascorbate is a necessary cofactor and redox-active micronutrient, whereas evidence that isolated vitamin C supplementation improves PMOS outcomes remains insufficient.Proposal: Prospectively test whether prespecified metabolic, neuroendocrine, and ascorbate measures enhance external prediction, decision-making, or clinical outcomes compared with high-quality guideline-concordant care. Conclusion: We endorse the PMOS consensus and propose a disconfirmable nutritional–redox research extension, not a revised clinical guideline, diagnostic axis, or established orthomolecular therapy.

Abstract as supplied by the indexing source. © the authors / publisher.